Intestinal permeability in colorectal cancer patients treated by raltitrexed or irinotecan.
Melichar
Bohuslav
B
Dvorák
Josef
J
Kohout
Pavel
P
Melicharová
Karolina
K
Solichová
Dagmar
D
Zadák
Zdenek
Z
D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D005260:Female; D006801:Humans; D007413:Intestinal Mucosa / Q000378:metabolism*; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D010539:Permeability; D011799:Quinazolines / Q000627:therapeutic use*; D013876:Thiophenes / Q000627:therapeutic use*
D000964:Antimetabolites, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D011799:Quinazolines; D013876:Thiophenes; D000077146:Irinotecan; C068874:raltitrexed; D002166:Camptothecin